Insights

Here’s why the EMvision share price surged 8% on Wednesday

Investors appear happy about an agreement EMvision has struck with tech company Keysight Technologies.
The post Here’s why the EMvision share price surged 8% on Wednesday appeared first on The Motley Fool Australia. –

The EMvision Medical Devices Ltd (ASX: EMV) share price has emerged from a trading halt on Wednesday morning, and shot 8% into the green.

Prior to their halt, EMVision shares closed at $1.94. Upon returning to trade, they have been sitting in the green amid the release of a company announcement. At the time of writing, EMvision shares are swapping hands at $2.05.

What did EMVision announce?

The company advised it has entered into an original equipment manufacturer (OEM) agreement with Keysight Technologies Inc (NYSE: KEYS).

According to the release, “Keysight is the world leader in radiofrequency (RF) test and measurement technology”. Specifically, the company signed its agreement with Keysight’s Australian subsidiary.

Under the agreement, EMvision will receive exclusive supply for ‘fast sweep’ features in the vector network analyser (VNA).

For reference, EMvision says the VNA is a custom solution developed in collaboration with Keysight.

“The VNA is a high performance, lower component count, miniaturised module responsible for accurate signal measurement,” states the release.

“The custom VNA represents a strategic investment by Keysight into the electromagnetic imaging sector.”

Regarding the announcement, EMvision CEO Dr Ron Weinberger says the collaboration “has been first class”.

This Agreement recognises the roles that both parties have played in the development of the bespoke VNA over a period of 3 years. I would like to thank the Keysight team for their concerted work in developing a best-of-breed solution for EMvision and look forward to the commercial phase of our relationship.

Noteworthy is that Keysight is not a medical device manufacturer. However, it does possess “the strongest portfolio of Vector Network Analysers (VNA), which are core to the sensors that are being used inside EMvision’s portable brain scanner,” says the company.

The agreement builds on a relationship that spawned back in 2019. Then, the pair entered into a strategic collaboration to develop “custom healthcare-focused VNA solutions”.

EMvision share price snapshot

In the last 12 months the EMvision share price has fallen more than 38%. Meanwhile, it is 23.5% in the red since trading resumed this year.

Following this announcement, shares have bounced from a low point and are tracking back towards monthly highs.

The post Here’s why the EMvision share price surged 8% on Wednesday appeared first on The Motley Fool Australia.

Should you invest $1,000 in EMvision Medical Devices right now?

Before you consider EMvision Medical Devices, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and EMvision Medical Devices wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

Why the AVZ share price went from being up 19% to down 20% today
ASX 200 mining shares slump, dragging index into the red
What’s the outlook for the Telstra share price in May?
Why did the AFIC share price go backwards in April?
‘Stupid and evil’. Warren Buffett and Charlie Munger unload on Bitcoin

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended EMvision Medical Devices Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!